For years, the most powerful people in tech have been making a bet.
Sam Altman had a group chat with fellow tech CEOs — a literal betting pool — for the year the first one-person billion-dollar company would appear. Dario Amodei, CEO of Anthropic, was asked directly when it would happen. His answer: 2026. The crowd applauded, awkwardly.
Nobody was thinking about Matthew Gallagher.
Gallagher is 41, self-taught, and grew up in a trailer park in Los Angeles. He is not a Silicon Valley insider. He did not raise venture capital. He did not hire a team of engineers, designers, or marketers. In September 2024, he launched Medvi — a telehealth platform selling GLP-1 weight-loss drugs — from his house, with $20,000 and more than a dozen AI tools.
In its first full year of operation, Medvi generated $401 million in sales. In 2026, it is on track to hit $1.8 billion. The New York Times was given access to Medvi’s financials to verify these numbers. They checked out.
The Matthew Gallagher Medvi one-person billion-dollar company story is not a thought experiment anymore. It has audited revenue figures.
How He Actually Built It
Gallagher used AI for almost everything. He used ChatGPT, Claude, and Grok to write the code powering his platform. AI generated his website copy, his ad images, and his customer-facing videos. He built AI systems to track business performance in real time. When he needed customer service, AI handled it.
What he did not try to build himself was the medical infrastructure. Instead, he partnered with CareValidate and OpenLoop Health — companies that handle licensed physicians, pharmacies, drug shipping, and regulatory compliance. His job was branding, marketing, and growth. AI handled the execution.
In its first month, Medvi had 300 customers. The second month: 1,300. The word Gallagher used to describe early growth was simple: “insane.”
Also Read: Yann LeCun Launches AMI Labs
CareValidate’s own team was baffled. They kept asking if he had people working behind the scenes. He did not. OpenLoop’s CEO Jon Lensing eventually stopped being surprised. “Matthew’s native tongue seems to be AI,” he said.
The Numbers That Change the Argument
The Matthew Gallagher Medvi one-person billion-dollar company story becomes more striking when you compare it to the established players in the same market.
Hims and Hers, one of Medvi’s direct competitors, has over 2,400 employees. In 2025, it posted a net profit margin of 5.5%. Medvi, with two people — Gallagher and his brother Elliot, hired in April 2025 — posted a net profit margin of 16.2%. Total net profit: between $65 million and $80 million on $401 million in revenue.
By the end of 2025, Medvi had 250,000 customers. Gallagher has already reinvested profits into expansion. A men’s health line launched in February 2026 hit 50,000 customers in its first month. Women’s health, hormone therapy, hair growth, and supplements are next.
His only regret about hiring? He tried contractors first. “It just increased my costs, and then it delayed my decision-making because I had more people to deal with,” he said.
The Critics Are Partly Right — And Entirely Missing the Point
The most common pushback on the Medvi story is that the GLP-1 market did the heavy lifting. Americans were desperately seeking affordable weight-loss drugs without a doctor’s appointment. Gallagher timed the wave perfectly.
That is true. And it is irrelevant.
The Matthew Gallagher Medvi one-person billion-dollar company was not built because GLP-1 drugs are popular. It was built because one person could now construct, operate, and scale an entire commercial infrastructure using AI tools that cost a few hundred dollars a month. He didn’t ride the wave. He built the surfboard — alone, in sixty days.
The GLP-1 market has dozens of competitors. Most of them needed teams, funding rounds, and years. Gallagher needed a laptop and $20,000.
What This Means
The prediction that a one-person billion-dollar company was coming was treated, until recently, as a fun thought experiment for tech conferences. Altman’s betting pool was a novelty. Amodei’s answer of “2026” got an awkward applause.
Medvi just made it a case study.
The implications are structural, not inspirational. If one person can build and operate a company at this scale — with better margins than 2,400-person competitors — the assumptions underneath hiring, team-building, and startup fundraising need to be revisited.
Gallagher himself summed up where he is now, emotionally, in a line to the Times: “For the first time, I’m not in survival mode.”
The one-person billion-dollar company is no longer the future of business. It is the present. And it has a name: Medvi.
